Posts

Intellia Therapeutics Advances In Vivo CRISPR Therapy Lonvo-z to FDA After Positive Phase 3 HAELO Trial Results

on

Compass Pathways Stock Soars on Second Phase 3 Success for Psilocybin Depression Treatment

on

Cogent Biosciences Soars on Positive Phase 3 PEAK Results in Gastrointestinal Stromal Tumors (GIST)

on

Inhibrx to Seek FDA Approval in 2026 After Strong Phase 2 Data for Bone Cancer Drug Ozekibart

on

Exelixis' Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review

on

Satellos Advances Duchenne Pill Trial in Children; Idorsia Raises $81 Million

on

Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA

on

Apnimed Advances FDA Filing after Second Pivotal Win for Oral Sleep Apnoea Drug

on

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

on

GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero's Stock Surges

on

Merck's HIV Combo Treatment Advances Towards FDA Filing

on

Kura Oncology and Kyowa Kirin Report Positive Phase 2 Results for Ziftomenib in AML, Prepare for FDA Submission

on